English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

: The overall efficacy of therapeutic monoclonal antibodies (mAbs) for asthma control in patients with uncontrolled eosinophilic asthma remains to be fully characterized. We conducted a meta-analysis of randomized controlled trials (RCTs) to analyze the ef cacies of new therapeutic mAbs, such as anti-interleukin (IL)-13 therapies, anti-IL4/13 therapies, and anti-IL-5 therapies, compared with that of a placebo in patients with uncontrolled asthma. This meta-analysis complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary efficacy outcome was asthma control as assessed by Asthma Control Questionnaire (ACQ) scores. Pooled estimates are presented as standardized mean differences (Std MDs) with 95% con dence intervals (CIs). Seven RCTs of therapeutic mAbs, including anti-IL-13, anti-IL-4/13, and anti-IL-5, met the criteria for study inclusion. The overall Std MD of changes in the ACQ score was -0.31 (95% CI, -0.45 to -0.17 ; P<0.0001). These results strongly indicate that therapeutic mAbs are effective in controlling asthma in patients with uncontrolled eosinophilic asthma.

Effectiveness of Therapeutic Monoclonal Antibodies for Asthma Control in Uncontrolled Eosinophilic Asthma